ProNAi Therapeutics is a drug development company advancing targeted therapeutics for the treatment of patients with cancer. We are an ambitious oncology drug development company oriented towards registration and commercialization. We have a world-class management team with a proven track record of success in oncology drug development and we intend to build a broad and diverse pipeline of promising oncology assets against emerging targets on the leading edge of cancer biology.
Our portfolio includes PNT141, a potent, selective and orally bioavailable small molecule inhibitor of Cdc7. This kinase is a key regulator of both DNA replication and DNA damage response, making it a compelling emerging target for the potential treatment of a broad range of tumor types.